I linje med given guidning Omsättningen i kvartalet uppgick till EUR 22,8m, vilket motsvarar en till...
Redeye updates on Northbaze following Q4 results, which were weaker than expected on the topline but...
With proof-of-performance for its proprietary digital technique for detection of high-sensitive biom...
Avslutar året med ett rekordkvartal Nettoomsättningen i kvartalet uppgick till 768 mkr, vilket motsv...
Gold Town Games publicerade den 22 februari år 2024 bolagets delårsrapport för det fjärde kvartalet ...
Redeye provides a research update following the Q4 report published by Initiator Pharma earlier toda...
Redeye leaves its initial comments on Heliospectras’ Q4 2023 report, in which the figures were sligh...
Dovre Q4 results topped our estimates due to Project Personnel.
Angler Gaming levererade en kv4 2023-rapport över vår förväntan både avseende intäkter och på lönsam...
Scanfil’s Q4 top line developed flat as expected, while the EUR 13.
Devyser fortsätter leverera på sin tillväxtagenda och ingår nya avtal som adderar tydliga konkurrens...
Redeye saw a sales development that was a bit softer than expected.
Adj. EBITA SEK 26.6m (+1% vs. ABGSCe 26.4m) Q4 implies no material changes on adj.
Adj. EBITDA ~60% below ABGSCe ACV growth of 3% q-o-q Negative consensus estimate revisions likely Q...
Redeye comments on Pagero's Q4 2023 report, which was in line on net sales, while margins were weake...
Net sales, EPS and dividend proposal were in line with consensus (LSEG) in Q4 but EBIT margin was be...
Sales +17% org., EBIT margin 7.6% (ABGSCe 5.6%), good FCF Encouraging momentum, Q4 beat in isolation...
Redeye provides an update on Thunderful Group following its Q4 2023 report, which showed weak number...
Redeye updates its estimates and valuation following ADDvise releasing its Q4 2023 report, which fea...
Redeye reviews BioInvent’s fourth quarter. The company now has six active clinical programs with sev...
.jpg)
